JMP Securities Maintains Outperform on Spruce Biosciences, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains an 'Outperform' rating on Spruce Biosciences (NASDAQ:SPRB) and raises the price target from $7 to $8.
August 16, 2023 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spruce Biosciences' stock rating has been maintained as 'Outperform' by JMP Securities, with a raised price target from $7 to $8.
The 'Outperform' rating indicates that the analyst believes Spruce Biosciences will do better than the market average. This, combined with the raised price target, suggests a positive outlook for the company's stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100